Just weeks ahead of the planned resubmission of the FDA new drug application for a pain pill tailored to reduce opioid-induced nausea and vomiting (OINV), one-time backer Daiichi Sankyo Co. Ltd. is handing rights to the drug back to Charleston Laboratories Inc. and booking a ¥27.8 billion (US$252.7 million) loss on the project as it reevaluates its U.S. pain drug strategy.